Jade Biosciences, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Jade Biosciences, Inc. (JBIO) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $6.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-10
- Jade Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $6.50M, a 174.04% increase year-over-year.
- Jade Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $4.74M, a 224.97% increase year-over-year.
- Jade Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.91M, a 96966.67% increase year-over-year.
- Jade Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.37M, a 38.60% decline year-over-year.
- Jade Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $9.94M, a 12.09% decline from fiscal 2024.
- Jade Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $11.31M, a 5.00% decline from fiscal 2023.
- Jade Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $11.91M, a 117.42% increase from fiscal 2022.
- Jade Biosciences, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $5.48M, a 168.04% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $6.50M 10-Q · filed 2026-08-10 | $11.24M derived: sum of 2 quarters · filed 2026-08-10 | |||
| 2026-03-31 | $4.74M 10-Q · filed 2026-08-10 | ||||
| 2025-12-31 | $9.94M 10-K · filed 2026-03-06 | ||||
| 2025-09-30 | $2.91M 10-Q · filed 2025-11-14 | $5.29M derived: sum of 2 quarters · filed 2026-08-10 | $6.74M derived: sum of 3 quarters · filed 2026-08-10 | ||
| 2025-06-30 | $2.37M 10-Q · filed 2026-08-10 | $3.83M derived: sum of 2 quarters · filed 2026-08-10 | |||
| 2025-03-31 | $1.46M 10-Q · filed 2026-08-10 | $1.19M 10-Q · filed 2025-04-25 | |||
| 2024-12-31 | $179.00K 10-K · filed 2026-03-06 | $11.31M 10-K · filed 2025-03-27 | |||
| 2024-09-30 | $3.00K 10-Q · filed 2025-11-14 | $2.00M 10-Q · filed 2024-11-12 | $3.87M derived: sum of 2 quarters · filed 2025-11-14 | $8.07M derived: sum of 3 quarters · filed 2025-11-14 | |
| 2024-06-30 | $3.87M 10-Q · filed 2024-11-12 | $8.06M derived: sum of 2 quarters · filed 2025-04-25 | |||
| 2024-03-31 | $4.20M 10-Q · filed 2025-04-25 | ||||
| 2023-12-31 | $11.91M 10-K · filed 2025-03-27 | ||||
| 2023-09-30 | $3.24M 10-Q · filed 2024-11-12 | $6.27M derived: sum of 2 quarters · filed 2024-11-12 | $8.65M derived: sum of 3 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $3.03M 10-Q · filed 2024-11-12 | $5.42M derived: sum of 2 quarters · filed 2024-11-12 | |||
| 2023-03-31 | $2.38M 10-Q · filed 2024-11-12 | ||||
| 2022-12-31 | $5.48M 10-K · filed 2024-03-25 | ||||
| 2022-09-30 | $1.50M 10-Q · filed 2023-11-13 | $2.72M derived: sum of 2 quarters · filed 2023-11-13 | $3.75M derived: sum of 3 quarters · filed 2023-11-13 | ||
| 2022-06-30 | $1.22M 10-Q · filed 2023-11-13 | $2.25M derived: sum of 2 quarters · filed 2023-11-13 | |||
| 2022-03-31 | $1.02M 10-Q · filed 2023-11-13 | ||||
| 2021-12-31 | $2.04M 10-K · filed 2023-03-29 | ||||
| 2021-09-30 | $845.00K 10-Q · filed 2022-11-14 | $1.17M derived: sum of 2 quarters · filed 2022-11-14 | $1.19M derived: sum of 3 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $321.00K 10-Q · filed 2022-11-14 | $344.00K derived: sum of 2 quarters · filed 2022-11-14 | |||
| 2021-03-31 | $23.00K 10-Q · filed 2022-11-14 | ||||
| 2020-12-31 | $58.00K 10-K · filed 2022-03-30 | ||||
| 2020-09-30 | $21.00K 10-Q · filed 2021-11-15 | $27.00K derived: sum of 2 quarters · filed 2021-11-15 | $34.00K derived: sum of 3 quarters · filed 2021-11-15 | ||
| 2020-06-30 | $6.00K 10-Q · filed 2021-11-15 | $13.00K derived: sum of 2 quarters · filed 2021-11-15 | |||
| 2020-03-31 | $7.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |